Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease

Shieh Yueh Yang, Ming Jang Chiu, Ta Fu Chen, Herng Er Horng

Research output: Contribution to journalReview article

15 Citations (Scopus)

Abstract

Alzheimer’s disease (AD) is the most common form of dementia. The development of assay technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers, such as amyloid and total Tau protein, are among the most promising diagnostic methods due to their low cost, low risk, and ease of operation. However, such biomarkers in blood occur at extremely low levels and are difficult to detect precisely. In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR), was developed. IMR involves the use of antibody-functionalized magnetic nanoparticles dispersed in aqueous solution. The concentrations of detected molecules are converted to reductions in the ac magnetic susceptibility of this reagent due to the association between the magnetic nanoparticles and molecules. To achieve ultra-high sensitivity, a high-Tc superconducting-quantum-interference-device (SQUID) ac magnetosusceptometer was designed and applied to detect the tiny reduction in the ac magnetic susceptibility of the reagent. Currently, a 36-channeled high-Tc SQUID-based ac magnetosusceptometer is available. Using the reagent and this analyzer, extremely low concentrations of amyloid and total Tau protein in human plasma could be detected. Further, the feasibility of identifying subjects in early-stage AD via assaying plasma amyloid and total Tau protein is demonstrated. The results show a diagnostic accuracy for prodromal AD higher than 80% and reveal the possibility of screening for early-stage AD using SQUID-based IMR.

Original languageEnglish
Pages (from-to)37-56
Number of pages20
JournalNeurology and Therapy
Volume6
DOIs
Publication statusPublished - 2017 Jul 1

Fingerprint

Early Diagnosis
Alzheimer Disease
Biomarkers
Amyloid
tau Proteins
Equipment and Supplies
Nanoparticles
Technology
Hematologic Tests
Dementia
Costs and Cost Analysis
Antibodies

Keywords

  • Alzheimer’s disease
  • Immunomagnetic reduction
  • Magnetic nanoparticles
  • Plasma biomarkers
  • SQUID

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Cite this

Detection of Plasma Biomarkers Using Immunomagnetic Reduction : A Promising Method for the Early Diagnosis of Alzheimer’s Disease. / Yang, Shieh Yueh; Chiu, Ming Jang; Chen, Ta Fu; Horng, Herng Er.

In: Neurology and Therapy, Vol. 6, 01.07.2017, p. 37-56.

Research output: Contribution to journalReview article

@article{295cdec2aab8476d97b04c017f1c90aa,
title = "Detection of Plasma Biomarkers Using Immunomagnetic Reduction: A Promising Method for the Early Diagnosis of Alzheimer’s Disease",
abstract = "Alzheimer’s disease (AD) is the most common form of dementia. The development of assay technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers, such as amyloid and total Tau protein, are among the most promising diagnostic methods due to their low cost, low risk, and ease of operation. However, such biomarkers in blood occur at extremely low levels and are difficult to detect precisely. In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR), was developed. IMR involves the use of antibody-functionalized magnetic nanoparticles dispersed in aqueous solution. The concentrations of detected molecules are converted to reductions in the ac magnetic susceptibility of this reagent due to the association between the magnetic nanoparticles and molecules. To achieve ultra-high sensitivity, a high-Tc superconducting-quantum-interference-device (SQUID) ac magnetosusceptometer was designed and applied to detect the tiny reduction in the ac magnetic susceptibility of the reagent. Currently, a 36-channeled high-Tc SQUID-based ac magnetosusceptometer is available. Using the reagent and this analyzer, extremely low concentrations of amyloid and total Tau protein in human plasma could be detected. Further, the feasibility of identifying subjects in early-stage AD via assaying plasma amyloid and total Tau protein is demonstrated. The results show a diagnostic accuracy for prodromal AD higher than 80{\%} and reveal the possibility of screening for early-stage AD using SQUID-based IMR.",
keywords = "Alzheimer’s disease, Immunomagnetic reduction, Magnetic nanoparticles, Plasma biomarkers, SQUID",
author = "Yang, {Shieh Yueh} and Chiu, {Ming Jang} and Chen, {Ta Fu} and Horng, {Herng Er}",
year = "2017",
month = "7",
day = "1",
doi = "10.1007/s40120-017-0075-7",
language = "English",
volume = "6",
pages = "37--56",
journal = "Neurology and Therapy",
issn = "2193-8253",
publisher = "Springer Healthcare",

}

TY - JOUR

T1 - Detection of Plasma Biomarkers Using Immunomagnetic Reduction

T2 - A Promising Method for the Early Diagnosis of Alzheimer’s Disease

AU - Yang, Shieh Yueh

AU - Chiu, Ming Jang

AU - Chen, Ta Fu

AU - Horng, Herng Er

PY - 2017/7/1

Y1 - 2017/7/1

N2 - Alzheimer’s disease (AD) is the most common form of dementia. The development of assay technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers, such as amyloid and total Tau protein, are among the most promising diagnostic methods due to their low cost, low risk, and ease of operation. However, such biomarkers in blood occur at extremely low levels and are difficult to detect precisely. In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR), was developed. IMR involves the use of antibody-functionalized magnetic nanoparticles dispersed in aqueous solution. The concentrations of detected molecules are converted to reductions in the ac magnetic susceptibility of this reagent due to the association between the magnetic nanoparticles and molecules. To achieve ultra-high sensitivity, a high-Tc superconducting-quantum-interference-device (SQUID) ac magnetosusceptometer was designed and applied to detect the tiny reduction in the ac magnetic susceptibility of the reagent. Currently, a 36-channeled high-Tc SQUID-based ac magnetosusceptometer is available. Using the reagent and this analyzer, extremely low concentrations of amyloid and total Tau protein in human plasma could be detected. Further, the feasibility of identifying subjects in early-stage AD via assaying plasma amyloid and total Tau protein is demonstrated. The results show a diagnostic accuracy for prodromal AD higher than 80% and reveal the possibility of screening for early-stage AD using SQUID-based IMR.

AB - Alzheimer’s disease (AD) is the most common form of dementia. The development of assay technologies able to diagnose early-stage AD is important. Blood tests to detect biomarkers, such as amyloid and total Tau protein, are among the most promising diagnostic methods due to their low cost, low risk, and ease of operation. However, such biomarkers in blood occur at extremely low levels and are difficult to detect precisely. In the early 2000s, a highly sensitive assay technology, immunomagnetic reduction (IMR), was developed. IMR involves the use of antibody-functionalized magnetic nanoparticles dispersed in aqueous solution. The concentrations of detected molecules are converted to reductions in the ac magnetic susceptibility of this reagent due to the association between the magnetic nanoparticles and molecules. To achieve ultra-high sensitivity, a high-Tc superconducting-quantum-interference-device (SQUID) ac magnetosusceptometer was designed and applied to detect the tiny reduction in the ac magnetic susceptibility of the reagent. Currently, a 36-channeled high-Tc SQUID-based ac magnetosusceptometer is available. Using the reagent and this analyzer, extremely low concentrations of amyloid and total Tau protein in human plasma could be detected. Further, the feasibility of identifying subjects in early-stage AD via assaying plasma amyloid and total Tau protein is demonstrated. The results show a diagnostic accuracy for prodromal AD higher than 80% and reveal the possibility of screening for early-stage AD using SQUID-based IMR.

KW - Alzheimer’s disease

KW - Immunomagnetic reduction

KW - Magnetic nanoparticles

KW - Plasma biomarkers

KW - SQUID

UR - http://www.scopus.com/inward/record.url?scp=85025116170&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85025116170&partnerID=8YFLogxK

U2 - 10.1007/s40120-017-0075-7

DO - 10.1007/s40120-017-0075-7

M3 - Review article

AN - SCOPUS:85025116170

VL - 6

SP - 37

EP - 56

JO - Neurology and Therapy

JF - Neurology and Therapy

SN - 2193-8253

ER -